Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Nkarta, Inc. (NKTX) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 57.3 M | 105.6 M | 378.89 M | 253.07 M | |
| 2022 | 49.69 M | 100.73 M | 472.94 M | 354.89 M | |
| 2021 | -48,357,000 | 22.94 M | 273.9 M | 240.19 M | |
| 2020 | -87,773,000 | 16.43 M | 337.65 M | 315.33 M | |
| 2019 | -13,310,642 | 73.89 M | 48.41 M | 37.47 M |